On May 19, 2024 CiMaas reported that it will provide CYTEA BIO with the GMP-grade K562-F012 feeder cells for the expansion of its umbilical cord blood-derived NK cells (Press release, CiMaas, MAY 19, 2024, View Source [SID1234643429]). Conversely, CYTEA BIO will supply CiMaas with Pin antibodies for the pre-arming of CiMaas NK cells to assess the benefit it brings and the opportunity to pursue a longer-term partnership.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CYTEA BIO is a Swiss/French biotech company dedicated to developing cell therapeutics using its patented Pin platform. This unique approach allows pre-arming Fc-engineered targeting ligands onto genetically unmodified effector cells to orientate and harness a naturally occurring cytotoxicity process. With this platform, an infinite number of products can be envisaged, with ligands and/or effector cells being interchanged. Pre-arming human allogeneic NK cells with Fc-Engineered antibodies (PinTM antibodies) highlighted the power of this strategy, improving the functional and targeted cytotoxicity of the NK cells against various cancer models. CYTEA BIO has initiated a lead development program using pre-armed human allogeneic NK cells with Pin anti-EGFR antibody for the treatment of glioblastoma multiforme.